Myasthenia gravis: a personal view of pathogenesis and mechanism, part 2.
A review of our current knowledge of the etiology and pathogenesis of myasthenia gravis is presented, with particular emphasis on the immunological aspects of the disease. Part 1, published in the January/February issue of MUSCLE & NERVE, dealt with the clinical and genetic features of myasthenia gravis which led to the autoimmune theory of the etiology of the disease. Part 2, which appears in this issue, provides a review of the dysfunction of physiology, pharmacology, and structure of the neuromuscular junction in myasthenia gravis, and the part played by the autoimmune process.
D001327:Autoimmune Diseases; D003650:Decamethonium Compounds; D006801:Humans; D008564:Membrane Potentials; D009045:Motor Endplate / Q000648:ultrastructure; D009132:Muscles / Q000378:metabolism; D009157:Myasthenia Gravis / Q000209:etiology* / Q000473:pathology; D009469:Neuromuscular Junction / Q000503:physiopathology; D005082:Physical Exertion; D011950:Receptors, Cholinergic / Q000502:physiology; D009435:Synaptic Transmission; D014403:Tubocurarine
D003650:Decamethonium Compounds; D011950:Receptors, Cholinergic; D014403:Tubocurarine